JP2019511221A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511221A5
JP2019511221A5 JP2018547931A JP2018547931A JP2019511221A5 JP 2019511221 A5 JP2019511221 A5 JP 2019511221A5 JP 2018547931 A JP2018547931 A JP 2018547931A JP 2018547931 A JP2018547931 A JP 2018547931A JP 2019511221 A5 JP2019511221 A5 JP 2019511221A5
Authority
JP
Japan
Prior art keywords
nucleic acid
virus
dengue
deletion
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018547931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511221A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/021989 external-priority patent/WO2017156511A1/en
Publication of JP2019511221A publication Critical patent/JP2019511221A/ja
Publication of JP2019511221A5 publication Critical patent/JP2019511221A5/ja
Withdrawn legal-status Critical Current

Links

JP2018547931A 2016-03-11 2017-03-11 弱毒化された生ジカウイルスワクチン Withdrawn JP2019511221A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307170P 2016-03-11 2016-03-11
US62/307,170 2016-03-11
PCT/US2017/021989 WO2017156511A1 (en) 2016-03-11 2017-03-11 Live attenuated zika virus vaccine

Publications (2)

Publication Number Publication Date
JP2019511221A JP2019511221A (ja) 2019-04-25
JP2019511221A5 true JP2019511221A5 (cg-RX-API-DMAC10.html) 2020-03-05

Family

ID=58428363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018547931A Withdrawn JP2019511221A (ja) 2016-03-11 2017-03-11 弱毒化された生ジカウイルスワクチン

Country Status (11)

Country Link
US (1) US20190194260A1 (cg-RX-API-DMAC10.html)
EP (1) EP3426292A1 (cg-RX-API-DMAC10.html)
JP (1) JP2019511221A (cg-RX-API-DMAC10.html)
KR (1) KR20180127397A (cg-RX-API-DMAC10.html)
CN (1) CN109152828A (cg-RX-API-DMAC10.html)
AU (1) AU2017230112A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018068342A2 (cg-RX-API-DMAC10.html)
CA (1) CA3016697A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018010874A2 (cg-RX-API-DMAC10.html)
MX (1) MX2018010958A (cg-RX-API-DMAC10.html)
WO (1) WO2017156511A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
WO2018152158A1 (en) * 2017-02-14 2018-08-23 Shi Pei Yong Live attenuated zika virus with 3'utr deletion, vaccine containing and use thereof
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
GB201716307D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Chimeric yellow fever zika virus strain
EP3710046A4 (en) 2017-11-10 2021-11-17 The Research Institute at Nationwide Children's Hospital RECOMBINANT VECTORS CODING FOR PROTEIN SUBUNITIES OF THE ZIKA VIRUS
WO2020051080A1 (en) * 2018-09-04 2020-03-12 The Board Of Regents Of The University Of Texas System Dna plasmid-launched live-attenuated vaccines for plus-sense single stranded rna viruses
MX2022000038A (es) * 2019-06-25 2022-02-24 Codagenix Inc Virus del dengue atenuados.
EP4277641A4 (en) * 2021-02-26 2025-03-19 Duke University Compositions for and methods of improving gene therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001059093A2 (en) 2000-02-10 2001-08-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services FULL-LENGTH INFECTIOUS cDNA CLONES OF TICK BORNE FLAVIVIRUS
CA2755964C (en) * 2001-05-22 2017-06-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
CA2472468C (en) 2002-01-10 2015-11-24 Alexander G. Pletnev Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
ES2355719T3 (es) 2002-05-03 2011-03-30 The United States Government As Represented By The Department Of Health And Human Services Vacuna contra el dengue que contiene una deleción común de 30 nucleótidos en la utr en 3' del dengue tipos 1 y 2.
US7622113B2 (en) 2003-12-08 2009-11-24 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
US7851194B2 (en) 2004-06-14 2010-12-14 The United States Of America As Represented By The Department Of Health And Human Services West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines
DK2054428T3 (da) * 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine
US20100316670A1 (en) 2007-06-14 2010-12-16 Blaney Joseph E Chimeric sle/dengue type 4 antigenic viruses
US20120294889A1 (en) * 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines

Similar Documents

Publication Publication Date Title
Hombach Vaccines against dengue: a review of current candidate vaccines at advanced development stages
Huang et al. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development
Guirakhoo et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine
Durbin et al. Dengue vaccine candidates in development
Sun et al. Basic amino acid substitution at residue 367 of the envelope protein of Tembusu virus plays a critical role in pathogenesis
JP2015524421A5 (cg-RX-API-DMAC10.html)
WO2017156511A8 (en) Live attenuated zika virus vaccine
WO2008022196A3 (en) Development of dengue virus vaccine components
JP2017526689A5 (cg-RX-API-DMAC10.html)
GB2550418A (en) An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
Lai et al. Evaluation of molecular strategies to develop a live dengue vaccine
RU2020132280A (ru) Аттенуированные флавивирусы
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
Abbo et al. Comparative efficacy of Mayaro virus-like particle vaccines produced in insect or mammalian cells
Kamath et al. Dengue vaccines: Current status and future perspectives
He et al. Replication/assembly defective avian flavivirus with internal deletions in the capsid can be used as an approach for living attenuated vaccine
Babaeimarzangou et al. Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families
Dias et al. DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model
JP2018502080A5 (cg-RX-API-DMAC10.html)
WO2018129160A1 (en) Live attenuated flavivirus vaccines and methods of using and making same
Schepp-Berglind et al. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses
EP2086526B1 (en) Induction of an immune response against Dengue virus using prime-boost approach
Baize et al. Recent advances in vaccines against viral haemorrhagic fevers
Chambers et al. Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice
US20220168412A1 (en) Chimeric Zika-Japanese Encephalitis Virus